OBJECTIVES: Coronary heart disease (CHD) is the most common cause of mortality worldwide. The burden of CHD causes 27,14 % of total mortality in Tunisia. Statins are the leading molecules in CHD prevention. The national insurance fund paid 9% of its total drug expenditures in 2015 in statins. INASanté has launched an HTA study aiming to compare the intensification of statin monotherapy versus a combination therapy for the prevention of CHD in patients with moderate to high cardiovascular risk. This study aims to reduce prescription variability and not justified therapies. METHODS: Research was carried out on the basis of HTA on the net from 2006 to 2016. Title, abstract and full text screening, was performed by two independent reviewers, using prespecified eligibility criteria. A critical appraisal was performed using INAHTA, PRISMA checklists, FLC 2.0 and EUnetHTA adaptation toolkit. One review from Agency for Healthcare Research and quality (AHRQ) elaborated in 2014 was retained. An adaptation process has been started. We gathered lipid lowering agents’ consumption data from key institutions and we started a qualitative study through interviews with cardiologists and general practitioners from public and private sector and representatives from scientific societies. Interviews will be computerized and analyzed using NVIVO. After discussing the results with the working group the report will be synthesized and validated. RESULTS:   According to AHRQ report, all evidence for clinical outcomes were graded insufficient when comparing the therapies. Effect on lowering LDL-C depends on the combination agent. In Tunisia, according to the first interviews, the only combination reported is with fibrates, in case of associated hypertriglyceridemia. BAS are no more prescribed; Ezetimibe has not yet obtained the marketing authorization. CONCLUSIONS:   There are significant differences among practitioners in prescription habits. This can be related to the populations’ characteristics, availability of molecules and lack of common guidelines.